{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-068543","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.015165+00:00","generated_at":"2026-05-22T00:21:36.623668+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"medium","headline":"Invivyd launches discovery program for measles monoclonal antibody; candidate target by 2025","bullets":["Multiple healthcare providers have requested a monoclonal antibody for measles treatment and post-exposure prophylaxis from Invivyd.","Goal is to identify a preclinical measles mAb candidate in 2025; progress update expected by end of year.","Over 20 million Americans are unvaccinated; U.S. at risk of losing functional elimination as vaccination rates decline.","No approved therapies currently exist for measles; current options include high-dose Vitamin A and IVIG, both with limitations."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-068543","json":"https://secwatch.observer/filing/0000950170-25-068543.json","markdown":"https://secwatch.observer/filing/0000950170-25-068543.md","text":"https://secwatch.observer/filing/0000950170-25-068543.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000095017025068543/0000950170-25-068543-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000095017025068543/ivvd-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T00:21:36.623668+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}